Daniel L. Simmons

Not to be confused with the Daniel L. Simmons who is a law professor at the University of California, Davis.

For other people named Daniel Simmons, see Daniel Simmons.

Daniel L. Simmons is a professor of chemistry and the director of the Cancer Research Center at Brigham Young University (BYU). He was the discoverer of the COX-2 enzyme that is the target of celecoxib (Celebrex) and other COX-2 inhibitors. He and BYU felt that Pfizer had not properly credited or paid them for Simmons work in this development and brought a suit against Pfizer.

Simmons has bachelors and masters degrees from BYU. He earned his Ph.D. from the University of Wisconsin in 1986. From 1986-1989 he held a post-doctoral Fellowship at Harvard University.

Simmons discovered the COX-2^[1] and COX-3 enzymes.

References

1. ^ Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (April 1991). "Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing". Proceedings of the National Academy of Sciences of the United States of America 88 (7): 2692–6. doi:10.1073/pnas.88.7.2692. PMC 51304. PMID 1849272. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=51304. 

Sources

• Thomson, Linda (October 28, 2009). "Judge orders Pfizer to pay BYU $852K for suit delays". Deseret News. http://www.deseretnews.com/article/705340277/Judge-orders-Pfizer-to-pay-BYU-852K-for-suit-delays.html. 
• BYU Chemistry Department bio of Simmons
• Zoom business info collection of articles on Simmons
• Utah Science medals awards including a short bio of Simmons

Persondata
Name	Simmons, Daniel L.
Alternative names
Short description
Date of birth
Place of birth
Date of death
Place of death